Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tvardi Therapeutics Inc (TVRD)

Tvardi Therapeutics Inc (TVRD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 39,291
  • Shares Outstanding, K 9,377
  • Annual Sales, $ 7,140 K
  • Annual Income, $ -70,870 K
  • EBIT $ -31 M
  • EBITDA $ -31 M
  • 60-Month Beta 0.20
  • Price/Sales 5.51
  • Price/Cash Flow N/A
  • Price/Book 1.19

Options Overview Details

View History
  • Implied Volatility 196.46% ( -139.94%)
  • Historical Volatility 519.97%
  • IV Percentile 55%
  • IV Rank 24.97%
  • IV High 449.63% on 10/21/25
  • IV Low 112.20% on 10/23/25
  • Put/Call Vol Ratio 0.05
  • Today's Volume 21
  • Volume Avg (30-Day) 201
  • Put/Call OI Ratio 0.32
  • Today's Open Interest 2,413
  • Open Int (30-Day) 2,516

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/25
See More
  • Average Estimate -0.83
  • Number of Estimates 3
  • High Estimate -0.68
  • Low Estimate -0.98
  • Prior Year -5.40
  • Growth Rate Est. (year over year) +84.63%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.85 +10.13%
on 11/07/25
7.23 -41.36%
on 10/16/25
-37.36 (-89.81%)
since 10/10/25
3-Month
3.85 +10.13%
on 11/07/25
43.65 -90.29%
on 10/10/25
-19.36 (-82.03%)
since 08/12/25
52-Week
3.85 +10.13%
on 11/07/25
43.65 -90.29%
on 10/10/25
-8.04 (-65.46%)
since 11/12/24

Most Recent Stories

More News
SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Examining Potential Securities Law Violations at Tvardi

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Tvardi To Contact Him Directly To Discuss Their Options...

TVRD : 4.24 (+1.19%)
Tvardi Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven...

TVRD : 4.24 (+1.19%)
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson  Encourages Investors Who Suffered Significant Losses In Tvardi To Contact Him Directly To Discuss Their Options

TVRD : 4.24 (+1.19%)
TVRD Investors Have Opportunity to Join Tvardi Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tvardi Therapeutics, Inc. (“Tvardi” or “the Company”)...

TVRD : 4.24 (+1.19%)
Investigation Alert: Tvardi Therapeutics, Inc. (TVRD) Under Scrutiny - Contact Levi & Korsinsky for Details

New York, New York--(Newsfile Corp. - October 31, 2025) - Levi & Korsinsky notifies investors that it has commenced an investigation of Tvardi Therapeutics, Inc. ("Tvardi Therapeutics, Inc.") (NASDAQ:...

TVRD : 4.24 (+1.19%)
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson  Encourages Investors Who Suffered Significant Losses In Tvardi To Contact Him Directly To Discuss Their Options

TVRD : 4.24 (+1.19%)
ATTENTION TVRD Investors: Securities Fraud Investigation Underway - Contact Levi & Korsinsky

New York, New York--(Newsfile Corp. - October 27, 2025) - Levi & Korsinsky notifies investors that it has commenced an investigation of Tvardi Therapeutics, Inc. ("Tvardi Therapeutics, Inc.") (NASDAQ:TVRD)...

TVRD : 4.24 (+1.19%)
Rosen Law Firm Encourages Tvardi Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – TVRD

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Tvardi Therapeutics, Inc. (NASDAQ: TVRD) resulting...

TVRD : 4.24 (+1.19%)
Lost Money on Tvardi Therapeutics, Inc. (TVRD)? Contact Levi & Korsinsky to Protect Your Rights

New York, New York--(Newsfile Corp. - October 24, 2025) - Levi & Korsinsky notifies investors that it has commenced an investigation of Tvardi Therapeutics, Inc. ("Tvardi Therapeutics, Inc.") (NASDAQ:...

TVRD : 4.24 (+1.19%)
Faruqi & Faruqi Reminds Tvardi Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 3, 2025 - TVRD

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson  Encourages Investors Who Suffered Significant Losses In Tvardi To Contact Him Directly To Discuss Their Options

TVRD : 4.24 (+1.19%)

Business Summary

Tvardi Therapeutics Inc. is a privately held, clinical-stage, biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. Tvardi Therapeutics Inc., formerly known as Cara Therapeutics Inc.,...

See More

Key Turning Points

3rd Resistance Point 4.67
2nd Resistance Point 4.52
1st Resistance Point 4.38
Last Price 4.24
1st Support Level 4.08
2nd Support Level 3.93
3rd Support Level 3.79

See More

52-Week High 43.65
Fibonacci 61.8% 28.45
Fibonacci 50% 23.75
Fibonacci 38.2% 19.05
Last Price 4.24
52-Week Low 3.85

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar